

Journal für

# Gynäkologische Endokrinologie

Gynäkologie • Kontrazeption • Menopause • Reproduktionsmedizin

**Die Mädchensprechstunde: Expert Opinion - Intrauterine**

**Contraception: The Biggest Challenge**

Wildemeersch D, Goldstuck N

*Journal für Gynäkologische Endokrinologie 2016; 10 (1)*

*(Ausgabe für Österreich), 22-23*

*Journal für Gynäkologische Endokrinologie 2016; 10 (1)*

*(Ausgabe für Schweiz), 22-23*

**Offizielles Organ der Österreichischen  
IVF-Gesellschaft**

**Offizielles Organ der Österreichischen  
Menopause-Gesellschaft**

Indexed in EMBASE/Scopus/Excerpta Medica

[www.kup.at/gynaekologie](http://www.kup.at/gynaekologie)

Member of the



**Homepage:**

[www.kup.at/gynaekologie](http://www.kup.at/gynaekologie)

**Online-Datenbank mit  
Autoren- und Stichwortsuche**

Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz

P. h. b. GZ07Z007636M · Verlagspostamt: 3002 Parkersdorf · Erscheinungsort: 3003 Gablitz

**Unsere Räucherkegel** fertigen wir aus den feinsten **Kräutern** und **Hölzern**, vermischt mit dem wohlriechenden **Harz** der **Schwarzföhre**, ihrem »Pech«. Vieles sammeln wir wild in den Wiesen und Wäldern unseres **Bio-Bauernhofes** am Fuß der Hohen Wand, manches bauen wir eigens an. Für unsere Räucherkegel verwenden wir reine **Holzkohle** aus traditioneller österreichischer Köhlerlei.

»Eure Räucherkegel sind einfach wunderbar.  
Bessere Räucherkegel als Eure sind mir nicht bekannt.«  
– Wolf-Dieter Storl

synthetische  
**OHNE**  
Zusätze

# Waldweihrauch

»Feines Räucherwerk  
aus dem *Schneeberg*«  
L A N D



[www.waldweihrauch.at](http://www.waldweihrauch.at)

# Die Mädchensprechstunde

## Expert Opinion: Intrauterine Contraception: The Biggest Challenge

D. Wildemeersch<sup>1</sup>, N. D. Goldstuck<sup>2</sup>

<sup>1</sup>Gynecological Outpatient Clinic and IUD Training Center, Ghent, Belgium; <sup>2</sup>Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Western Cape, South Africa

In many ways IUDs are the near ideal form of long-acting reversible contraception and are strategically important for family planning in general and for preventing unintended pregnancies in particular. Their ability to reduce unintended pregnancy is governed by women *continuing* to use them, whereby the *tolerability of the device* has shown to be paramount to achieving this objective.

It is clear that contraceptive methods which are dependent on memory and motivation, such as the pill, are not the ideal solution in all women but especially younger age groups. For years, the pill has been synonymous with contraception. This has regrettably helped to maintain ignorance of contraceptive alternatives beyond condoms and sterilization. The impact is even more dramatic when one realizes that most if not all of these alternatives have demonstrated superior effectiveness over the pill.

With IUDs the inherent efficacy is so high, and proper and consistent use is almost guaranteed. A multitude of studies have demonstrated the extremely low pregnancy rates associated with copper and hormonal releasing devices. Sadly, only limited progress has been made in making conventional IUDs more acceptable to women. Unfortunately, many IUDs still have unacceptable high discontinuation rates. Recommendations by experts have been neglected, sometimes in favour of the interests of industry. Many women are, therefore, still underserved in most parts of the world as there are still no suitable intrauterine contraceptives to fulfill the needs of women.


Almost 50 years ago, a study in 60 nulliparous women found an average uterine cavity width of  $23.5 \pm 0.94$  mm [1]. The

**Table 1:** Transverse width in the fundus of the uterus in 165 nulliparous women [4].


	Range	50 <sup>th</sup> percentile measure	No (%) under 50 <sup>th</sup> percentile
Fundal width (mm)	13.8–35.0	24.4	101 (62.7)

authors stressed the importance of an optimal interrelationship between the IUD and the uterine cavity as fewer side effects and greater acceptability would thereby be promoted. They found that pain during use of the IUD is related to the disparity between the size of the uterine cavity and that of the IUD. Particularly a too wide IUD was found to be cumbersome. In later years, additional studies were conducted that examined the uterine width at the fundal level (fundal transverse diameter) in parous as well as nulliparous women using a measuring instrument. These studies found that the mean width of the uterine cavity in 795 nulliparous and parous women between 15 and 40 years of age is approximately 24 to 26 mm [2]. These findings have since been substantiated using less invasive external modern uterine imaging techniques that allow for precise and accurate uterine measurements *in vivo* [3]. The uterine cavity width was recently measured with 2-D ultrasound in a study in Finland conducted in 165 young nulliparous women, and found a *median* transverse fundal diameter of the uterine cavity of 24.4 mm. One hundred and one (62.7 %) women had a transverse diameter at the fundus of less than 24.4 mm (Table 1) [4].

Thus, a very large segment of the female population have substantially smaller uterine widths. The width of the normal uterine cavity was also assessed through 3-dimensional ultra-



**Figure 1:** (A) 3-D ultrasound picture of the frameless copper IUD in a uterine cavity with width of 11.44 mm. (B) Same in a uterine cavity width measuring 26.19 mm in width. (C) Hysteroscopic view after insertion in nulliparous women demonstrating the optimal relationship of the IUD with the narrow uterine cavity.



**Figure 2:** (A) Ω-shaped LNG-IUD with flexible transverse arm allowing adaptation to different cavity widths; (B) 3-D ultrasound of FibroPlant® LNG illustrating the harmony with the very small uterine cavity in a young woman which is only 17.80 mm wide.

sonography, as illustrated in this report. This technique allows for multiple images to be collected along with precise uterine dimensions of not only the width but also the length of the uterine cavity itself.

### ■ The biggest challenge

From a technical perspective, the biggest challenge is to design intrauterine contraceptive devices that fit like a shoe [5]. IUDs can be designed to fit uterine cavities of virtually every size and shape. The frameless IUD is an example as this device is suitable for insertion in all women regardless that their uterine cavity is small or large (Fig. 1). The device is frameless lacking any crossarms, is flexible and when inserted properly, the majority of women will keep the IUD for the full lifespan of the IUD.

Research is underway to make frameless devices that will last for more than 10 years which could be used from adolescence until the woman is ready to have her first child which is around the age of 30 in Europe on average. Frameless devices do not penetrate the market quickly as thorough training is required. Therefore, also other IUD options are being developed that take into account the various widths of uterine cavities and have the ability to adapt without causing trauma to the uterus. Figure 2 shows a Ω-shaped IUD which can adapt to the width of the uterine cavity without distorting the cavity; and the frameless Fibroplant LNG-IUD which is anchored to the fundus of the uterus using an identical anchor as GyneFix.

This editorial suggests, in agreement with others, that measuring of the uterine width should be considered prior to selecting an IUD for insertion [3, 6]. Frameless IUDs hold promise as no considerations of uterine width or shape is necessary. Insertion is simple and easy to learn by skilled providers. New framed IUDs that can adapt to various sizes of uterine cavities are currently under development and could be suitable for many women. The main focus of researchers should be on tolerability and at the same time optimal retention should be realized. Furthermore, new drug delivery systems should be

developed, both frameless and framed that release active ingredients providing contraception and treatment of various conditions such as heavy menstrual bleeding, dysmenorrhea, adenomyosis, or fibromyoma simultaneously. Other challenges are the prevention of sexual transmission of infectious diseases (e.g., HPV, HIV) in conjunction with the provision of contraception.

### ■ Conflict of Interest

Dirk Wildemeersch has conducted research in the field of non-hormonal and hormonal, framed and frameless intrauterine devices, including in nulliparous and adolescent women, for 30 years. Norman Goldstuck conducted research in intrauterine device use, including adolescents, for over 30 years.

### References:

1. Tejuja S, Malkani PK. Clinical significance of correlation between size of uterine cavity and IUCD: a study by planimeter-hystero-gram technique. *Am J Obstet Gynecol* 1969; 105: 620–7.
2. Kurz KH. Cavimeter uterine measurements and IUD clinical correlation. In: Zatuchni GI, Goldsmith A, Sciarra JJ (eds). *Intrauterine Contraception: Advances and Future Prospects*. Harper and Row, Philadelphia, 1984; 142–62.
3. Benacerraf BR, Shipp TD, Lyons JG, et al. Width of the normal uterine cavity in premenopausal women and effect of parity. *Obstet Gynecol* 2010; 116: 305–10.
4. Kaislasuo J, Heikinheimo O, Lähteenmäki P, et al. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception. *Hum Reprod* 2015; 30: 1580–8.
5. Goldstuck N, Hasskamp T, Jandi S, et al. Geometric foundations of intrauterine device complications and implications for IUD users – importance of the IUD size to maximize tolerability and prevent early discontinuation. *J Reproduktionsmed Endokrinol\_Online* 2015; 12: 255–9.
6. Liang H, Li L, Yuan W, et al. Dimensions of the endometrial cavity and intrauterine device expulsion or removal for displacement: a nested case-control study. *BJOG* 2014; 121: 997–1004.

### Korrespondenzadresse:

Dr. Alessandra Tramontana  
Geburtshilflich-Gynäkologische Abteilung  
Sozialmedizinisches Zentrum Ost – Donauespital  
A-1120 Wien, Langobardenstraße 122  
E-Mail: [allessandra.tramontana@wienkav.at](mailto:allessandra.tramontana@wienkav.at)

# Mitteilungen aus der Redaktion

## Besuchen Sie unsere zeitschriftenübergreifende Datenbank

[Bilddatenbank](#)

[Artikeldatenbank](#)

[Fallberichte](#)

## e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.

Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.

Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

[Bestellung e-Journal-Abo](#)

## Haftungsausschluss

Die in unseren Webseiten publizierten Informationen richten sich **ausschließlich an geprüfte und autorisierte medizinische Berufsgruppen** und entbinden nicht von der ärztlichen Sorgfaltspflicht sowie von einer ausführlichen Patientenaufklärung über therapeutische Optionen und deren Wirkungen bzw. Nebenwirkungen. Die entsprechenden Angaben werden von den Autoren mit der größten Sorgfalt recherchiert und zusammengestellt. Die angegebenen Dosierungen sind im Einzelfall anhand der Fachinformationen zu überprüfen. Weder die Autoren, noch die tragenden Gesellschaften noch der Verlag übernehmen irgendwelche Haftungsansprüche.

Bitte beachten Sie auch diese Seiten:

[Impressum](#)

[Disclaimers & Copyright](#)

[Datenschutzerklärung](#)